A guide to the FTSE 350: The Companies and Markets Show
Jennifer Johnson talks about the recently published GSK results, which showed strong growth, but the ongoing Zantac litigation is hanging over the shares. The team also touch on the prospects of rival pharma companies AstraZeneca and Indivior. Our US-based journalist Arthur Sants joins from New York to unpack the…
We score an episode from what we can actually measure — its reach and engagement, what listeners say about it, and what it covers. We don't have those signals for this one yet, so it doesn't get a number.
Buzzmeter says it's buzzing across platforms — the Hive Vote says whether the people who actually listened liked it.
Rate this episode
Add your vote to the Hive — listeners rate every episode after they finish.
- No reviews yet — be the first.
More from Investors' Chronicle
See all episodes →
Similar episodes from other shows
More like Investors' Chronicle →
Counting the cost of Marks & Spencer’s cyber-attack, and AstraZeneca versus GSK
Big deals in Big Pharma
A crunchy week for chipmakers
Is the FTSE 100 finally having its moment in the sun?
One great episode in your inbox, daily — free.
One email a day, unsubscribe anytime. No spam, ever.